A monoclonal antibody (WT1) for detecting leukemias of T-cell precursors (T-ALL).
A monoclonal antibody (WT1) for detecting leukemias of T-cell precursors (T-ALL).
复制标题
用于检测 T 细胞前体白血病 (T-ALL) 的单克隆抗体 (WT1)。
作者：
L. Vodinelich;W. Tax;Y. Bai;S. Pegram;P. Capel;M. Greaves
一种名为WT1的单克隆抗t抗体的选择性已在906例白血病和淋巴瘤中进行了评估。在急性淋巴细胞白血病中，WT1与未经治疗或复发患者的胸腺急性淋巴细胞白血病（ALL）细胞发生全面和选择性反应，从而克服了这种癌症广泛的抗原多样性和所涉及细胞类型的不成熟。80例胸腺All均为wt1阳性。此外，18例假定的胸腺前ALL也是wt1阳性，但与其他成熟相关的t细胞标志物无反应。表型WT1+ HLA-DR TdT+似乎是T-ALL所特有的，因此可以系统地用于鉴别诊断这种预后不良的ALL亚型。几乎所有的all病例现在都可以归入代表T细胞或b细胞谱系转化前体的两个主要亚群之一。WT1鉴定出约40,000 mol wt的单个多肽，与先前描述的两种单克隆抗体相似。
The selectivity of a monoclonal anti-T antibody, designated WT1, has been assessed in a series of 906 leukemias and lymphomas. In acute lymphoblastic leukemias, WT1 reacts comprehensively and selectively with thymic acute lymphoblastic leukemia (ALL) cells in untreated or relapsed patients, thus overriding the extensive antigenic diversity of this cancer and the immaturity of the cell type involved. All 80 cases of thymic ALL examined were WT1-positive. In addition, 18 cases of presumptive prethymic ALL were also WT1-positive, but were unreactive with other maturation-linked T-cell markers. The phenotype WT1+ HLA-DR TdT+ appears to be unique to T-ALL and can therefore be used systematically for the differential diagnosis of this poor prognosis subtype of ALL. Virtually all ALL cases can now be placed into one of two major subgroups representing transformed precursors of either the T- or B-cell lineage. WT1 identifies a single polypeptide of approximately 40,000 mol wt and is similar to two previously described monoclonal antibodies.